`
`July 28, 2006
`
`Russell Katz
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Division of Neurology Products
`5901-B Ammendale Road
`Beltsville, MD 20705-1266
`
`RE:
`
`IND 73,061 : BG00012 (Dimethyl Fumarate): Multiple Sclerosis
`End-of-Phase 2 Meeting (Type B) Briefing Package
`Serial No.: 0006
`
`Dear Dr. Katz.
`Reference is made to the Type B meeting {End of Phase 2) scheduled on August 30,
`2006 {from 15:00 to 16:30) for BG00012, which is being developed by Biogen Idee for
`the treatment of patients with relapsing-remit1ing multiple sclerosis (MS).
`In anticipation of the meeting, Biogen Idee is submitting 9 copies of the meeting briefing
`document (9 desk copies on CD), in addition to an electronic copy.
`
`The agenda, proposed meeting participants and sponsor questions are provided in
`Section 3 of the briefing document.
`
`Should you have any questions regarding !his request, please contact Tammy Sarnelli a1
`(617) 679-3513 or myself.
`
`/
`
`Senior Vice President, Regulatory Affairs
`Phone (617) 679-3783
`Fax (617) 679-3170
`
`Biog:en Idee 14 Cnmbridge Cent.,, Carrbridge, MA02142 Phono 617 679 ?000 www.biogenl~ec.com
`
`Page 1 ofl
`
`Biogeo Exhibit 2327
`Coalition v. Biogeo
`IPR2015-01993
`
`